Roth Capital Maintains Buy on BioHarvest Sciences, Lowers Price Target to $8
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $10 to $8.
Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $10 to $8.
